Showing 3,061 - 3,080 results of 13,329 for search '(( significantly increased decrease ) OR ( significant ((greatest decrease) OR (small decrease)) ))', query time: 0.43s Refine Results
  1. 3061
  2. 3062
  3. 3063
  4. 3064
  5. 3065

    The Laboratory Animal Flow Diagram. by Xueqin lu (22250795)

    Published 2025
    “…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
  6. 3066

    <sup>1</sup>H NMR spectra for kylo-0603. by Xueqin lu (22250795)

    Published 2025
    “…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
  7. 3067

    <sup>13</sup>C NMR spectra for Kylo-0603. by Xueqin lu (22250795)

    Published 2025
    “…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
  8. 3068

    The structures of T3 and Kylo-0603. by Xueqin lu (22250795)

    Published 2025
    “…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
  9. 3069

    Synthesis process of Kylo-0603. by Xueqin lu (22250795)

    Published 2025
    “…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
  10. 3070

    ESI-HRMS spectra for Kylo-0603. by Xueqin lu (22250795)

    Published 2025
    “…This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. …”
  11. 3071

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
  12. 3072

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
  13. 3073

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
  14. 3074

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
  15. 3075

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
  16. 3076
  17. 3077
  18. 3078
  19. 3079
  20. 3080